Remove Bioinformatics Remove Pharma Companies Remove Regulation
article thumbnail

Country focus: Hungary carves out a niche in digital pharma

pharmaphorum

They go into bioinformatics”. In the past couple of years, Turbine worked with a number of big pharma companies, including Bayer, and has also started building its own pipeline, including a target delivering new biological insight in PARP inhibitor resistance. “We They go into bioinformatics.”. So what do they do?

article thumbnail

How digital is transforming the commercial leader’s role in biopharma

pharmaphorum

To compete now, companies need to own a larger portion of the treatment journey and the overall patient care experience. Commercial leaders should leverage the internal capabilities and centres of excellence that pharma companies are increasingly building. About BrightInsight.

Marketing 133
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Can technology help diversify clinical trials?

pharmaphorum

data processing systems that support bioinformatics modelling) and digital record systems (e.g. Once stakeholders are confident that technologies are adequately validated, selection based on scientific and ethical considerations can be presented to regulators in accordance with applicable legal and regulatory frameworks.

article thumbnail

GSK’s Maria Reyes Boceta-Muñoz Talks Vaccine Development in a Post-Pandemic World

XTalks

The EMA and other agencies have stringent regulations and guidelines that cover the design of clinical development programs for new vaccines intended to provide pre- and post-exposure prophylaxis against infectious diseases. It is affected by factors such as complacency, convenience, confidence and cultural factors.

Vaccine 96
article thumbnail

How Can Rapid mRNA Quantification Enhance Multivalent Vaccine Development?

XTalks

These methods often require extensive sample preparation, complex bioinformatics or specialized lab environments, making them less ideal for quality control and release testing, where multiple mRNA constructs are already mixed.

Vaccine 64